Related Experiment Video
Updated: Aug 16, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
In vitro toxicity evaluation in the development of new anticancer drugs-genistein glycosides
Joanna Popiołkiewicz1, Krzysztof Polkowski, Janusz S Skierski
1Flow Cytometry Laboratory National Institute of Public Health, Chelmska, 30/34, 00-725 Warsaw, Poland. joanpop@poczta.fm
Abstract:
In vitro cytotoxicity tests currently in use applied in the developmental stages of anticancer drug discovery are able to select the most potent compounds, but are not predictive of their potential toxicity. In this study, we have demonstrated the applicability of neutral red uptake assay using mouse fibroblasts Balb/c 3T3 cell line (3T3 NRU assay) for in vitro toxicity testing of newly synthesized genistein glycosides, the compounds that appear to show anticancer activity. We have also proven the compatibility of in-house 3T3 NRU assay with the prediction model for acute rodent oral toxicity testing, endorsed by NIEHS-ICCVAM workshop. The combined results from the cytotoxicity and the in vitro toxicity tests facilitated the selection of the most promising genistein derivatives, compounds G21 and G23, which were the most active and selective towards cancer cells. The comparison of predicted LD50 values revealed that almost all genistein derivatives are at least two-fold less toxic than the chemotherapeutics currently used in cancer therapy, which is very promising for this new group of compounds.
Insights
This study shows a new in vitro toxicity test for anticancer drug development. It identified promising genistein derivatives (G21 and G23) that are less toxic than current therapies.
Area of Science:
- Drug Discovery and Development
- Toxicology
- Cell Biology
Background:
- Current in vitro cytotoxicity tests lack predictive value for drug toxicity.
- Genistein glycosides show potential anticancer activity but require toxicity assessment.
Purpose of the Study:
- To evaluate the neutral red uptake (NRU) assay for in vitro toxicity testing of genistein glycosides.
- To assess the compatibility of the NRU assay with rodent oral toxicity prediction models.
- To identify promising genistein derivatives for anticancer drug development.
Main Methods:
- Utilized the 3T3 NRU assay with mouse fibroblasts (Balb/c 3T3 cell line).
- Validated the assay against NIEHS-ICCVAM-endorsed prediction models for acute oral toxicity.
- Assessed cytotoxicity and selectivity of synthesized genistein derivatives.
Main Results:
- The 3T3 NRU assay effectively predicted in vitro toxicity for genistein glycosides.
- Genistein derivatives G21 and G23 demonstrated high anticancer activity and selectivity.
- Predicted LD50 values indicated genistein derivatives are significantly less toxic than current chemotherapeutics.
Conclusions:
- The 3T3 NRU assay is a valuable tool for in vitro toxicity testing in anticancer drug discovery.
- Genistein derivatives G21 and G23 are promising candidates for further development.
- This new class of compounds offers a potentially safer alternative to existing cancer therapies.
